India’s Life Sciences Sector at a Turning Point: Can Innovation Scale?

引言

印度的生命科学领域已到达一个关键转折点。过去十年间，该国在生物技术创新方面取得了实质性进展，专利申请量增长超过四倍，创新管线资产增加1.5倍。然而，印度能否将这些早期成果转化为可持续的大规模创新引擎，仍是未知数。由波士顿咨询公司（BCG）与专注印度的医疗创新基金HealthKois联合发布的新报告指出，尽管潜力确实存在，但结构性差距可能会制约该领域的发展。

行业背景印度的制药业长期以来以仿制药生产和逆向工程闻名。然而，这一格局正在发生变化。报告指出，过去十年间，印度生物技术初创企业数量增长了1.6倍，流向医疗健康创新的私人资本大幅增加。尽管如此，创新故事仍处于“早期且不均衡”的阶段，大部分动力集中在后期转化。早期研究、临床执行、监管一致性以及早期资本获取仍然薄弱。几个里程碑事件凸显了进展。过去十年间，印度已诞生了11个新型药物资产，包括首创新化学实体、本土CAR-T疗法以及人工智能发现的分子。例如，Wockhardt的静脉抗生素Zaynich（头孢吡肟与齐德巴坦）于2026年6月获得FDA批准，用于治疗复杂性尿路感染。与此同时，Pandorum Technologies在2026年2月完成了1800万美元的B轮融资，以推进外泌体疗法并扩大全球生产规模。

过去五年中，私募股权和风险资本对印度医疗健康创新的投资增长了2.1倍，在2026财年达到7.31亿美元。资金涌入表明投资者信心增强，但报告警告称，其中大部分集中于后期阶段，导致早期初创企业资金不足。For global pharma and biotech companies, India’s innovation uptick presents both opportunities and challenges. On the one hand, India-origin science is increasingly being licensed by multinational pharmaceutical giants, and indigenously developed CAR-T therapies are being delivered at a fraction of global costs. This could eventually make India a competitive hub for novel drug discovery. On the other hand, structural inefficiencies—such as clinical trial approval times averaging 90 days versus 30 days in the U.S.—make it difficult to bring products to market quickly. Foreign partners may hesitate to collaborate if regulatory timelines remain unpredictable.

Challenges And Risks

• The report identifies several key barriers to scaling innovation in India:- Public funding gaps: Maximum grant sizes are around $52,000, compared to $2–3 million in the U.S. and EU.
• Low risk appetite: Indian venture capital firms are generally averse to high-risk biotech investments.
• Slow clinical approvals: Average clinical trial approval time of 90 days vs. ~30 days in the U.S.
• Import dependence: High-quality local suppliers for research-grade raw materials and reagents are scarce, especially for advanced modalities like gene therapy, leading to 30- to 45-day lead times.1. Building India’s first generation of specialist biotech capital – dedicated funds with deep scientific expertise to support early-stage ventures.
• 2. Encouraging academia-industry partnerships – stronger collaboration to translate research into commercial products.
• 3. Creating fast-track regulatory pathways – streamlined approvals for novel therapies.
• 4. Building a domestic supply chain – reducing import reliance for raw materials and reagents.
• 5. Bridging the R&D talent quality gap – investing in specialized training and education.## 结论

印度的生命科学领域正处于转折点，过去十年的进展为更具创新性的未来奠定了基础。未来的发展道路将在很大程度上取决于政府、学术界和私人资本如何合作，以弥补BCG-HealthKois报告中指出的结构性差距。随着全球对印度生物技术潜力的兴趣日益增长，印度迎来了从仿制药生产国向医疗创新真正枢纽转变的独特机遇。未来几年将检验其生态系统能否从充满希望的起点迈向可规模化的影响力。